Migraine prevalence, disease burden, and the need for preventive therapy

Richard B. Lipton, M. E. Bigal, M. Diamond, F. Freitag, M. L. Reed, W. F. Stewart

Research output: Contribution to journalArticle

1183 Citations (Scopus)

Abstract

OBJECTIVES: 1) To reassess the prevalence of migraine in the United States; 2) to assess patterns of migraine treatment in the population; and 3) to contrast current patterns of preventive treatment use with recommendations for use from an expert headache panel. METHODS: A validated self-administered headache questionnaire was mailed to 120,000 US households, representative of the US population. Migraineurs were identified according to the criteria of the second edition of the International Classification of Headache Disorders. Guidelines for preventive medication use were developed by a panel of headache experts. Criteria for consider or offer prevention were based on headache frequency and impairment. RESULTS: We assessed 162,576 individuals aged 12 years or older. The 1-year period prevalence for migraine was 11.7% (17.1% in women and 5.6% in men). Prevalence peaked in middle life and was lower in adolescents and those older than age 60 years. Of all migraineurs, 31.3% had an attack frequency of three or more per month, and 53.7% reported severe impairment or the need for bed rest. In total, 25.7% met criteria for "offer prevention," and in an additional 13.1%, prevention should be considered. Just 13.0% reported current use of daily preventive migraine medication. CONCLUSIONS: Compared with previous studies, the epidemiologic profile of migraine has remained stable in the United States during the past 15 years. More than one in four migraineurs are candidates for preventive therapy, and a substantial proportion of those who might benefit from prevention do not receive it.

Original languageEnglish (US)
Pages (from-to)343-349
Number of pages7
JournalNeurology
Volume68
Issue number5
DOIs
StatePublished - Jan 2007

Fingerprint

Migraine Disorders
Headache
Therapeutics
Bed Rest
Headache Disorders
Population
Epidemiologic Studies
Guidelines

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007). Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68(5), 343-349. https://doi.org/10.1212/01.wnl.0000252808.97649.21

Migraine prevalence, disease burden, and the need for preventive therapy. / Lipton, Richard B.; Bigal, M. E.; Diamond, M.; Freitag, F.; Reed, M. L.; Stewart, W. F.

In: Neurology, Vol. 68, No. 5, 01.2007, p. 343-349.

Research output: Contribution to journalArticle

Lipton, RB, Bigal, ME, Diamond, M, Freitag, F, Reed, ML & Stewart, WF 2007, 'Migraine prevalence, disease burden, and the need for preventive therapy', Neurology, vol. 68, no. 5, pp. 343-349. https://doi.org/10.1212/01.wnl.0000252808.97649.21
Lipton, Richard B. ; Bigal, M. E. ; Diamond, M. ; Freitag, F. ; Reed, M. L. ; Stewart, W. F. / Migraine prevalence, disease burden, and the need for preventive therapy. In: Neurology. 2007 ; Vol. 68, No. 5. pp. 343-349.
@article{a927a7cc628c460a8bdfaa56132d30e3,
title = "Migraine prevalence, disease burden, and the need for preventive therapy",
abstract = "OBJECTIVES: 1) To reassess the prevalence of migraine in the United States; 2) to assess patterns of migraine treatment in the population; and 3) to contrast current patterns of preventive treatment use with recommendations for use from an expert headache panel. METHODS: A validated self-administered headache questionnaire was mailed to 120,000 US households, representative of the US population. Migraineurs were identified according to the criteria of the second edition of the International Classification of Headache Disorders. Guidelines for preventive medication use were developed by a panel of headache experts. Criteria for consider or offer prevention were based on headache frequency and impairment. RESULTS: We assessed 162,576 individuals aged 12 years or older. The 1-year period prevalence for migraine was 11.7{\%} (17.1{\%} in women and 5.6{\%} in men). Prevalence peaked in middle life and was lower in adolescents and those older than age 60 years. Of all migraineurs, 31.3{\%} had an attack frequency of three or more per month, and 53.7{\%} reported severe impairment or the need for bed rest. In total, 25.7{\%} met criteria for {"}offer prevention,{"} and in an additional 13.1{\%}, prevention should be considered. Just 13.0{\%} reported current use of daily preventive migraine medication. CONCLUSIONS: Compared with previous studies, the epidemiologic profile of migraine has remained stable in the United States during the past 15 years. More than one in four migraineurs are candidates for preventive therapy, and a substantial proportion of those who might benefit from prevention do not receive it.",
author = "Lipton, {Richard B.} and Bigal, {M. E.} and M. Diamond and F. Freitag and Reed, {M. L.} and Stewart, {W. F.}",
year = "2007",
month = "1",
doi = "10.1212/01.wnl.0000252808.97649.21",
language = "English (US)",
volume = "68",
pages = "343--349",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Migraine prevalence, disease burden, and the need for preventive therapy

AU - Lipton, Richard B.

AU - Bigal, M. E.

AU - Diamond, M.

AU - Freitag, F.

AU - Reed, M. L.

AU - Stewart, W. F.

PY - 2007/1

Y1 - 2007/1

N2 - OBJECTIVES: 1) To reassess the prevalence of migraine in the United States; 2) to assess patterns of migraine treatment in the population; and 3) to contrast current patterns of preventive treatment use with recommendations for use from an expert headache panel. METHODS: A validated self-administered headache questionnaire was mailed to 120,000 US households, representative of the US population. Migraineurs were identified according to the criteria of the second edition of the International Classification of Headache Disorders. Guidelines for preventive medication use were developed by a panel of headache experts. Criteria for consider or offer prevention were based on headache frequency and impairment. RESULTS: We assessed 162,576 individuals aged 12 years or older. The 1-year period prevalence for migraine was 11.7% (17.1% in women and 5.6% in men). Prevalence peaked in middle life and was lower in adolescents and those older than age 60 years. Of all migraineurs, 31.3% had an attack frequency of three or more per month, and 53.7% reported severe impairment or the need for bed rest. In total, 25.7% met criteria for "offer prevention," and in an additional 13.1%, prevention should be considered. Just 13.0% reported current use of daily preventive migraine medication. CONCLUSIONS: Compared with previous studies, the epidemiologic profile of migraine has remained stable in the United States during the past 15 years. More than one in four migraineurs are candidates for preventive therapy, and a substantial proportion of those who might benefit from prevention do not receive it.

AB - OBJECTIVES: 1) To reassess the prevalence of migraine in the United States; 2) to assess patterns of migraine treatment in the population; and 3) to contrast current patterns of preventive treatment use with recommendations for use from an expert headache panel. METHODS: A validated self-administered headache questionnaire was mailed to 120,000 US households, representative of the US population. Migraineurs were identified according to the criteria of the second edition of the International Classification of Headache Disorders. Guidelines for preventive medication use were developed by a panel of headache experts. Criteria for consider or offer prevention were based on headache frequency and impairment. RESULTS: We assessed 162,576 individuals aged 12 years or older. The 1-year period prevalence for migraine was 11.7% (17.1% in women and 5.6% in men). Prevalence peaked in middle life and was lower in adolescents and those older than age 60 years. Of all migraineurs, 31.3% had an attack frequency of three or more per month, and 53.7% reported severe impairment or the need for bed rest. In total, 25.7% met criteria for "offer prevention," and in an additional 13.1%, prevention should be considered. Just 13.0% reported current use of daily preventive migraine medication. CONCLUSIONS: Compared with previous studies, the epidemiologic profile of migraine has remained stable in the United States during the past 15 years. More than one in four migraineurs are candidates for preventive therapy, and a substantial proportion of those who might benefit from prevention do not receive it.

UR - http://www.scopus.com/inward/record.url?scp=33846576913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846576913&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000252808.97649.21

DO - 10.1212/01.wnl.0000252808.97649.21

M3 - Article

C2 - 17261680

AN - SCOPUS:33846576913

VL - 68

SP - 343

EP - 349

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -